Podcast Episodes
Back to Search“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer
Episode 2
The addition of perioperative durvalumab in gastric and gastroesophageal junction cancer improved event-free survival, according to findings from the…
9 months, 2 weeks ago
What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now?
Season 1 Episode 1
Data from the SERENA-6 trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting, have the potential to dramatically change a…
9 months, 3 weeks ago
Practice-Changing “Inflection Point” Coming in ESR1-Positive Breast Cancer Care?
Editor’s Note: This interview was recorded shortly before the 2025 American Society of Clinical Oncology Annual Meeting.
Big questions associated wi…
10 months ago
When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next?
The approach to ESR1 and PIK3CA mutations in patients with hormone receptor–positive metastatic breast cancer continues to evolve. What role does cir…
10 months, 3 weeks ago
How “Remarkable Change” in EGFR-Mutated NSCLC Care Is Making a Difference for Patients
The last few years have seen “a remarkable change in both our approach and management of EGFR lung cancer,” says Shirish M. Gadgeel, MD, division hea…
11 months, 1 week ago
Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines
When it comes to tackling fertility issues associated with cancer, “oncology clinicians are often reluctant to talk about this because it is really n…
11 months, 2 weeks ago
“Second-Line ER-Positive Breast Cancer Has Just Become Very Complicated”
“Second-line [estrogen receptor (ER)]-positive breast cancer has just become very complicated,” says Erika P. Hamilton, MD, the director of breast ca…
11 months, 2 weeks ago
Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care?
Burnout among oncologists is a serious concern, and artificial intelligence (AI) represents a potential solution, says Debra Patt, MD, PhD, MBA, a pr…
11 months, 3 weeks ago
“Time to Move On”: How Targeted Therapies Are Transforming AML Care
The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, say…
1 year ago
ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout
Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (AS…
1 year, 1 month ago